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Background: Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule
gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory
activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment
methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between
GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate.
Methods: Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women
18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts) undergoing IVF with the GnRH
antagonist protocol were randomized to either the OCP or E2 pretreatment arms, with no restrictions such as blocking
or stratification. Authors involved in data collection and analysis were blinded to group assignment. Fifty patients
received OCP (30 μg ethinyl E2/150 μg levonorgestrel) for 12–16 days from day 1 or 2, and stimulation was started
5 days after stopping OCP. Similarly, 50 patients received 4 mg/day oral E2 valerate from day 20 for 5–12 days, until the
day before starting stimulation.
Results: Pretreatment with OCP (mean±SD, 14.5±1.7 days) was significantly longer than with E2 (7.8±1.9 days).
Stimulation and embryological characteristics were similar. Ongoing pregnancy rates (46.0% vs. 44.0%; risk
difference, –2.0% [95% CI –21.2% to 17.3%]), as well as implantation (43.5% vs. 47.4%), clinical pregnancy
(50.0% vs. 48.0%), clinical miscarriage (7.1% vs. 7.7%), and live birth (42.0% vs. 40.0%) rates were comparable
between groups.
Conclusions: This is the first study to directly compare these two methods of cycle scheduling in GnRH antagonist
cycles. Our results fail to show statistically significant differences in ongoing pregnancy rates between pretreatment
with OCP and E2 for IVF with the GnRH antagonist protocol. Although the study is limited by its sample size, our results
may contribute to a future meta-analysis. An interesting future direction would be to extend our study to women with
decreased ovarian reserve, as these are the patients in whom an increase in oocyte yield—due to the hypothetical
beneficial effect of steroid pretreatment on follicular synchronization—could more easily be demonstrated.
Trial registration: ClinicalTrials.gov NCT01501448.
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In the last decade, gonadotropin-releasing hormone
(GnRH) antagonist protocols have become increasingly
popular for controlled ovarian hyperstimulation (COH).
Their use offers several advantages over the long agonist
protocol [1], including shorter overall treatment dur-
ation, absence of perimenopausal symptoms caused by
pituitary desensitization, no risk of inadvertent adminis-
tration at the beginning of pregnancy or of ovarian cyst
formation, and a lower consumption of gonadotropins.
According to the conclusions of a recent meta-analysis
[2], similar live birth rates can be achieved with the use
of GnRH antagonist protocols, while significantly redu-
cing the risk of ovarian hyperstimulation syndrome,
compared to the long GnRH agonist protocol.
A potential disadvantage of GnRH antagonist protocols
is that, classically, stimulation is started on day 2 or 3 of
the menstrual cycle, which makes it difficult to schedule
stimulation and laboratory activities. Cycle scheduling can
be used to avoid weekend retrievals and to equally distrib-
ute the workload throughout the week, thereby avoiding
excessive opening of incubator doors and the associated
negative impact on embryo development, as well as redu-
cing the amount of unplanned work, which can result in
loss of concentration and reduced efficiency of the labora-
tory staff [3-5].
Both oral contraceptive pills (OCPs) and synthetic pro-
gestogens have been used for many years to schedule cy-
cles [6-9]. More recently, the use of natural estrogens
has also been advocated [10]. Estrogens primarily inhibit
FSH secretion, whereas progestogens are mainly in-
volved in the control of LH secretion.
Some smaller-scale studies on the hypothetical nega-
tive impact of OCPs on IVF cycles yielded controversial
results in terms of ongoing pregnancy rates [11,12],
while a recent meta-analysis, which summarized the re-
sults of six randomized controlled trials, found that on-
going pregnancy rates in normal responders were affected
by OCP pretreatment [13]. However, this meta-analysis
was confounded by the use of different OCPs for a varying
number of days and with a varying pill-free interval. As far
as the underlying mechanisms are concerned, it has been
postulated that the gestagen component of OCPs could
exert a negative impact on endometrial receptivity in the
subsequent cycle. Alternatively, low LH concentrations
after OCP pretreatment could impair oocyte competence
or endometrial receptivity when ovarian stimulation is
performed with recombinant FSH without LH [14]. How-
ever, in a recent randomized, controlled trial performed by
our group that used one type of OCP for a relatively
narrow range of days followed by a fixed pill-free period,
we did not find any significant differences in ongoing
pregnancy rates or live birth rates compared to the long
agonist protocol [15].The use of oral estrogens started in the midluteal phase
of the cycle preceding ovarian stimulation was proposed
recently for cycle scheduling purposes, based on the inhibi-
tory effect of estradiol (E2) on follicle growth through its
negative feedback on the increase in FSH during the lu-
teal–follicular transition [16], which stops as soon as E2 is
discontinued. Pretreatment with estrogens offers the ad-
vantage of a shorter duration of pretreatment than OCPs.
Previous studies showed that estrogen pretreatment does
not affect cycle outcome as compared to no pretreatment
[17-19] or to the long GnRH agonist protocol [20], while it
does promote follicular growth coordination during ovar-
ian stimulation [21]. However, none of the studies com-
pared treatment outcomes directly with those obtained
after scheduling with OCPs. The aim of our study was to
see whether these two methods of cycle scheduling are
equally effective in terms of ongoing pregnancy rate and
the secondary outcome measures detailed below.
Methods
Subjects
Between January and May 2012, we enrolled 118 women
who were undergoing an IVF–ICSI cycle at IVI Madrid
(Madrid, Spain). The inclusion criteria were age 18–
38 years, regular normo-ovulatory menstrual cycles (26–
35 days), body mass index (BMI) < 30 kg/m2, normal cycle
day-3 basal serum hormone levels (FSH < 10 IU/l and E2 <
60 pg/ml), and <3 previous IVF/ICSI attempts. Exclusion
criteria were previous ovarian surgery, low ovarian response
(cancellation of the cycle due to poor follicular development
after at least 7 days of gonadotropin stimulation, or <5 oo-
cytes retrieved) in a previous IVF/ICSI cycle, and polycystic
ovarian syndrome according to the Rotterdam criteria [22].
A total of 100 women were included in the study, with only
one cycle per patient (Figure 1). This project was approved
by our institutional review board, and all patients provided
written informed consent. The study was registered with
ClinicalTrials.gov (identifier: NCT01501448).
Randomization procedure
A study nurse randomized and assigned patients at the
time of cycle scheduling to either the OCP or E2 pretreat-
ment arms in 1:1 ratio, based on a computer-generated
random number list, with no restrictions such as blocking
or stratification. The sequence was concealed in opaque,
consecutively numbered envelopes until an intervention
was assigned. Patients meeting all inclusion criteria were
recruited consecutively. Authors involved in data collec-
tion and data analysis were blinded to group assignment.
Protocols
Patients randomized to the OCP group started with the
pill (30 μg of ethinyl E2 plus 150 μg of levonorgestrel
[Microgynon; Bayer Schering Pharma, Berlin, Germany])
Assessed for eligibility (n = 118)
Excluded  (n = 18)
Not meeting inclusion criteria (n = 18)
Declined to participate (n = 0)
Other reasons (n = 0)
Analysed (n = 50, under the ITT principle)
Excluded from analysis (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention
Stimulation cancelled due to low response
(n = 3)
No ET (no embryos available on day 3)
(n = 4)
Patients with ET (n = 43)
Allocated to intervention OCP (n = 50)
Received allocated intervention (n = 50)
Did not receive allocated intervention (n = 0) 
Lost to follow-up (n = 0)
Discontinued intervention
Stimulation cancelled due to low response
(n = 2)
No ET (no embryos available on day 3)
(n = 7)
Patients with ET (n = 41)
Allocated to intervention E2 (n = 50)
Received allocated intervention (n = 50)
Did not receive allocated intervention (n = 0)
Analysed (n = 50, under the ITT principle)




Randomized (n = 100)
Enrollment
Figure 1 CONSORT 2010 flowchart. Note: ITT = intention-to-treat.
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scheduled IVF/ICSI procedure, and they took it for 12–
16 days. As suggested by Cédrin-Durnerin et al. [23],
ovarian stimulation was initiated 5 days after discontinu-
ation of the pill, regardless of the specific day of the onset
of menses, with a daily dose of recombinant FSH
(Puregon; MSD, Oss, The Netherlands, or Gonal F; Merck
Serono, Madrid, Spain) ranging from 200 to 225 IU on the
first 5 days. From day 6 of stimulation, gonadotropin doses
were adjusted according to serum E2 levels and ovarian re-
sponse, which was assessed by vaginal ultrasound, every
2 days.
In patients allocated to the E2 arm of the study (n =
50), pretreatment with E2 valerate (Meriestra; Novartis
Farmacéutica, Barcelona, Spain) was started on day 20
of the cycle preceding the IVF/ICSI cycle at a daily dose
of 4 mg (2 mg twice a day) orally for 5–12 days, until
the day before the initiation of ovarian stimulation, in-
dependent of the specific day of onset of menstruation,
as it has been shown that the number of days by which
E2 pretreatment is extended beyond the menses does
not have a significant effect on cycle outcome [24].The number of pretreatment days in both groups was
chosen with the aim of starting stimulation between
Wednesday and Sunday and thus equally distributing
oocyte pickup among working days and minimizing
weekend retrievals, as coordinated by a designated per-
son at the centre.
In both groups, the GnRH antagonist ganirelix
(Orgalutran; MSD) was introduced at a daily dose of
0.25 mg when the leading follicle reached 13 mm in
mean diameter. Ovarian triggering was performed with
250 μg of recombinant human chorionic gonadotropin
(hCG) (Ovitrelle; Merck Serono), which was administered
as soon as two leading follicles reached ≥ 17 mm mean
diameter. Ovum pickup was performed 36 hours later.
IVF or ICSI was used to fertilize oocytes, according to in-
dividual requirements. A maximum of two embryos were
transferred on day 3, under ultrasound guidance. Luteal
support was started with 200 mg of micronized vaginal
progesterone (Progeffik 200; Laboratorios Alcalá Farma,
Alcalá de Henares, Spain) every 12 hours, beginning the
night after ovum pickup. Serum βhCG was evaluated
12 days after embryo transfer; a result of > 10 IU/l was
Table 2 Stimulation cycle parameters
Characteristics OCP (n = 50) E2 (n = 50) P value
Pretreatment days 14.5 ± 1.7 7.8 ± 1.9 <0.001
Stimulation days 10.0 ± 1.7 10.6 ± 1.5 0.09
Total FSH dose (IU) 1,627 ± 565 1,692 ± 488 0.54
Peak E2 (pg/ml) 1,527 ± 729 1,596 ± 774 0.84
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by transvaginal ultrasound 2 weeks later if βhCG was
positive.
Clinical pregnancy was defined as an intrauterine sac
with heartbeat 4 weeks after embryo transfer, whereas on-
going pregnancies were characterized by the presence of a
developing embryo at >12 weeks of gestation.
Sample size estimate
The primary outcome of the study was ongoing preg-
nancy rate. Secondary outcome variables were implant-
ation rate, clinical pregnancy rate, miscarriage rate, and
live birth rate.
Sample size calculations were based on the results of our
recently published previous study [15], in which ongoing
pregnancy rates in GnRH antagonist cycles pretreated with
OCP (47.8%) were compared with the GnRH agonist
protocol. Based on a two-sided significance level of 0.05
and a power of 80%, at least 1,555 cycles in each group
would have been necessary to detect a 5% difference in on-
going pregnancy rates. However, reaching a sample size
large enough for an adequately powered investigation is
not feasible for a single-centre study. Therefore, we arbi-
trarily chose the number of patients to be recruited in this
study to provide clinically useful data that could be incor-
porated into a future meta-analysis.
Statistical analysis
Categorical data are expressed as number and percentage,
and continuous data as mean ± standard deviation (SD).
For categorical variables, the χ2 test was used with continu-
ity correction, whereas continuous variables were analyzed
with Student’s t-test for independent samples, after testing
for normality. A P value of <0.05 was considered to be sta-
tistically significant. All statistical analyses were performed
with the SPSS 13.0 package (SPSS, Inc., Chicago, IL, USA).
Results
As presented in Table 1, both groups of patients (n = 50
in both groups) were comparable in terms of age, BMI,
and number of previous IVF attempts.
Due to the difference between the two pretreatment
protocols, significantly more days of pretreatment with
OCP compared to E2 (14.5 ± 1.7 vs. 7.8 ± 1.9 days, P <
0.001) were necessary before starting stimulation. All
parameters of stimulation that we analyzed (duration ofTable 1 Demographic characteristics of patients
Characteristics OCP (n = 50) E2 (n = 50)
Age (years) 33.9 ± 3.4 34.5 ± 3.1
BMI (kg/m2) 22.2 ± 3.6 20.9 ± 2.7
Previous IVF/ICSI attempts 0.5 ± 0.8 0.6 ± 0.9
Data are expressed as mean ± SD. There were no statistically significant
differences as analyzed with Student’s t-test for independent samples.stimulation, total amount of FSH used, and peak E2 and
progesterone levels) were comparable between the groups
(Table 2).
Stimulation was cancelled in three patients receiving
OCP pretreatment and two patients pretreated with E2
due to low response in all cases. Of those patients who
did undergo oocyte pickup (47 and 48 patients, respect-
ively), four and seven women did not reach the stage of
embryo transfer in the OCP and E2 groups, respectively,
because no embryos were available on day 3 (Figure 1).
No significant differences were observed in the number
of retrieved oocytes, fertilization rate, number of top-
quality embryos, or number of transferred embryos. With
regard to the outcome of the cycles, implantation rates,
total and clinical pregnancy rates, early clinical miscarriage
rates, and ongoing pregnancy rates and live birth rates
were all comparable between the two groups (there were
two late miscarriages in both groups) (Table 3). All ana-
lyses were based on the intention-to-treat principle. How-
ever, even an “as treated” analysis of the primary outcome
measure, based on 23/43 vs. 22/41 ongoing pregnancies,
would give a difference that remains far from statistical
significance (P = 0.84).
The proportion of oocyte retrievals performed on week-
end days was similar between the groups: 8.5% (4/47) with
OCP and 10.4% (5/48) with E2 pretreatment (P = 0.97)
(Figure 2). Both frequencies were significantly lower than
28.6%, which would be expected to occur by pure chance
(i.e., on 2 out of 7 days) (P = 0.03 for OCP and P = 0.04
for E2).
Discussion
Our results failed to show statistically significant differ-
ences for any measures of IVF treatment outcome between
pretreatment with OCP and E2 for COH with the GnRH
antagonist protocol. To the best of our knowledge, this is
the first study to directly compare these two methods of
cycle scheduling in GnRH antagonist cycles.Peak P (ng/ml) 0.6 ± 0.3 0.5 ± 0.2 0.52
Cancellation rate 6% (3/50) 4% (2/50) 0.99
Retrieved oocytes 9.6 ± 4.9 10.2 ± 6.0 0.61
Fertilization rate (%) 64.0 ± 19.4 61.3 ± 20.8 0.52
Top-quality embryos 3.0 ± 2.2 3.0 ± 2.4 0.93
Transferred embryos 1.6 ± 0.4 1.4 ± 0.6 0.07
Continuous data are expressed as mean ± SD.
Table 3 Treatment outcome parameters
Parameters OCP E2 Risk difference (%)
(95% CI)
P
value(n = 50) (n = 50)
Implantation ratea 43.5% (30/69) 47.4% (27/57) 3.9 0.79
(−13.4 to 21.1)
Pregnancy rate per cycle 56.0% (28/50) 52.0% (26/50) −4.0 0.84
(−23.1 to 15.4)
Clinical pregnancy rate per cycle 50.0% (25/50) 48.0% (24/50) −2.0 0.99
(−21.3 to 17.4)
Early clinical miscarriageb rate per pregnancy 7.1% (2/28) 7.7% (2/26) 0.6 0.66
(−16.4 to 18.3)
Ongoing pregnancy rate per cycle 46.0% (23/50) 44.0% (22/50) −2.0 0.99
(−21.2 to 17.3)
Live birth rate per cycle 42.0% (21/50) 40.0% (20/50) −2.0 0.99
(−21.0 to 17.1)
aImplantation rate is the number of intrauterine sacs with heartbeat / number of transferred embryos.
bClinical pregnancies with miscarriage at <12 weeks of gestation.
CI confidence interval.
Hauzman et al. Reproductive Biology and Endocrinology 2013, 11:96 Page 5 of 7
http://www.rbej.com/content/11/1/96Cédrin-Durnerin et al. showed a significantly higher
consumption of gonadotropins in OCP-pretreated cycles
as compared to either pretreatment with E2 or no pre-
treatment, with no significant differences in treatment
outcomes [23]. However, their study was mainly aimed at
examining changes in the hormonal environment and an-
tral follicles during the washout period after discontinu-
ation of different methods of steroid pretreatment, and it
included an even lower number of patients per treatment
arm. Their data showed that steroid pretreatments differ-
ently affect the hormonal environment before the start of
stimulation. According to their findings, it took 5 days
after stopping OCP for FSH and LH to return to baseline
levels from a strong suppression, suggesting this was an
optimal washout period in cycles pretreated with OCP. In
contrast, E2 pretreatment did not reduce FSH levels sig-
nificantly but rather avoided the increase of FSH duringFigure 2 Distribution of oocyte retrievals across days of the
week with OCP and E2 pretreatment, respectively. Note: Dashed
horizontal line at 14.3% (1/7) shows proportion of retrievals per day
expected to occur by pure chance.the luteal-follicular transition, and the rapid FSH rebound
after stopping natural estrogen intake argues for a short,
1–2 day washout interval. Indeed, we administered E2
until the day before the initiation of ovarian stimulation in
order to optimize the synchronization of endogenous and
exogenous FSH stimuli.
In a more recent study [19], the same group of re-
searchers hypothesized that a 1-day washout period was
too short to allow for complete recovery of baseline FSH
levels, and that this was responsible for the increased go-
nadotropin consumption as compared to cycles without
any pretreatment. However, no clinical studies have been
performed with COH started 2 days after stopping E2
administration.
Although the length of steroid exposure varied consider-
ably both within each pretreatment group and between
the two groups, previous studies have shown that the
number of pretreatment days – at least within the range
of days used in our study – has no impact on COH out-
comes in cycles pretreated with either E2 [24] or OCPs
[25]. There is, however, considerable difference between
OCPs in terms of their suppressive effect, depending on
their progestin component [26]. A recent, small-scale,
retrospective cohort study, performed in egg donors, sug-
gested that OCPs containing androgenic (estrane- and
gonane-derived) progestins lead to a more profound sup-
pression of follicular development than those with anti-
androgenic activity, resulting in lower oocyte yields [27].
The authors hypothesized that OCPs including an andro-
genic progestin would inhibit gonadotropin support for
the growing follicle but maintain androgen exposure,
which would lead to initial androgen-driven follicle growth
but, in the end, to atresia of growing follicles because of
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with anti-androgenic OCPs, lacking the androgen-driven
growth of small growing follicles and the growth support
from FSH, very small follicles would fail to grow but
would not undergo atresia either. Upon suspending OCPs,
and starting COH, these small follicles would then still
have the ability to resume growth and development, lead-
ing to ultimately larger oocyte yields than with androgenic
HCs. However, this hypothesis, based on retrospective
comparison of two relatively small groups, each receiving
several types of OCPs, needs to be confirmed by prospect-
ive studies. In fact, these findings would not affect the re-
sults of our study, as we used a single type of progestin
(levonorgestrel) in all our OCP-pretreated patients.
That weekend oocyte retrievals can be significantly re-
duced by using OCPs is well known [28]. Using this
method ensures that there is no need to prolong the fol-
licular phase by delaying administration of hCG, a prac-
tice that has been shown to result in lower pregnancy
rates if triggering is delayed by 2 days [29]. However, as
shown by Tremellen and Lane [30], a 1-day advance-
ment or delay of hCG administration does not adversely
impact IVF live birth outcomes. Earlier studies demon-
strated that E2 pretreatment can also be used for optimal
cycle scheduling by reducing weekend retrievals [18,24].
Moreover, extending E2 pretreatment beyond the menses
has no deleterious effect on COH outcomes [24]. Our re-
sults are in line with these findings, as the proportion of
oocyte retrievals performed on weekend days was signifi-
cantly reduced using either method (Figure 2). Although
the reduction in weekend retrievals was even more pro-
nounced in a study by Blockeel et al. [18] (1/37 in the E2
pretreatment group vs. 8/39 in patients without steroid
pretreatment), our aim was not to completely avoid week-
end pickups, but rather to distribute pickups evenly among
the days of the week, taking into consideration the lower
number of personnel working on weekends. In fact,
Blockeel et al. [18] initiated stimulation between Thursday
to Sunday, whereas our practice is to start gonadotropin
administration between Wednesday and Sunday. This one-
day difference might account for the more pronounced re-
duction in weekend pickups in their study.
A major limitation of our study is its sample size. In
fact, with 50 patients in each arm of the study, only a
difference of >26% could have been detected with 80%
power, at a 0.05 significance level. However, as men-
tioned earlier, our aim was to contribute our clinical
results to a future meta-analysis on the subject. An in-
teresting future direction would be to extend our study
to women with decreased ovarian reserve, as these are
the patients in whom an increase in oocyte yield—due
to the hypothetical beneficial effect of steroid pretreat-
ment on follicular synchronization—could more easily
be demonstrated. As far as the use of OCPs in poorresponders is concerned, a modification to the GnRH
antagonist protocol has been proposed by Orvieto et al.
[31] The so-called “ultrashort GnRH agonist/GnRH an-
tagonist protocol” is supposed to combine the beneficial
effects of OCP pretreatment with that of the gonado-
tropin flare induced by the GnRH agonist, which is ad-
ministered at the beginning of COH. The latter could
circumvent the alleged detrimental effect of the OCP
pretreatment on endogenous LH levels, which in turn
could impair oocyte competence or endometrial recep-
tivity. This protocol has been used with success in poor
responder patients [32]. However, no prospective stud-
ies have compared so far the efficacy of this combined
approach to other stimulation protocols.
Conclusions
In conclusion, we could not demonstrate differences in
clinical results by using either OCP or E2 pretreatment for
COH, if differences in washout periods after stopping pre-
treatment are accounted for, admitting, however, that the
study was underpowered for the detection of small differ-
ences. Our results support those of earlier studies demon-
strating that endogenous FSH suppression before starting
ovarian stimulation is an efficient way to schedule ovarian
stimulation in GnRH antagonist cycles. While observing
comparable clinical outcomes, the use of E2 might offer
several practical advantages compared to OCP: (1) Be-
cause E2 pretreatment is started in the midluteal phase,
preparation for a programmed stimulation with a GnRH
antagonist protocol can be scheduled in the same cycle
even if the patient expresses a desire to start treatment
after the early follicular phase. (2) Pretreatment is shorter
with E2 than with OCPs (5–12 vs. 12–16 days, respect-
ively, in our practice). (3) By using E2, GnRH antagonist cy-
cles can be started in a scheduled manner even in patients
who have objections to or present contraindications for tak-
ing OCPs even for a short period. Furthermore, by avoiding
OCP pretreatment, we can give them one more chance to
get pregnant spontaneously in the cycle preceding IVF.Competing interests
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